Items
Login
Register
Toggle Navigation
Key Regulatory Issues in Biosimilars
Quantity
Add to Cart
Back to Results
Recorded August 9, 2017 | On-Demand Webinar
In the seven years since the abbreviated pathway for U.S. licensure of biosimilars went into effect, biosimilars have become one of the fastest growing sectors of the pharmaceutical industry. This webinar will cover the Supreme Court’s recent decision on the “patent dance” and its impact on the timing of biosimilar launches and development strategy. The significant regulatory and policy questions regarding the labeling of interchangeable products, reference product exclusivity, and pharmacy substitution policies will also be discussed. Hear from FDA on biosimilar approvals and development programs, along with final, draft, and upcoming guidance documents and learn about the Biosimilars Council efforts to support the industry.
Joe Franklin, Associate Director for Policy, Therapeutic Biologics & Biosimilars Staff, Office of New Drugs, CDER, FDA
Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP
Christine Simmon, Senior Vice President of Policy and Strategic Alliances, Association of Accessible Medicines and Executive Director, Biosimilars Council
Moderated by John R. Manthei, Partner, Latham & Watkins LLP
IE and Edge users: Microsoft Internet Explorer (IE) and Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or
[email protected]
and we will assist you in your purchase.
Assign Members :
Members Assigned |
Assign all contacts
Unassign all contacts
View :
All
Assigned
Unassigned
Add New Contact
Add New Contact
Cancel
Save
Assign
Full Name
Account Name
Email
Role
Total Records
- Showing Page
Discounts and special pricing for additional items will be applied once you add the item to your cart.